Drug intelligence / Profile preview

PBP2102

Development stage: Preclinical
Lead developer: Prestige Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

PBP2102 is a monoclonal antibody biosimilar of pembrolizumab (Keytruda), currently under development by Prestige Biopharma (PBK). It is designed to target the Programmed Cell Death Protein 1 (PD-1) receptor on T cells. By binding to PD-1, PBP2102 blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby preventing the inhibition of T-cell activation and restoring the immune system's ability to recognize and attack tumor cells. The drug is being developed for the treatment of various solid tumors and is currently in the preclinical stage of development.

Other names: pembrolizumab biosimilarPBK PD-1 biosimilar

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on PBP2102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PBP2102.

Explore the full profile